普洛药业(000739)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

000739 普洛药业

已收盘 03-23 15:00:00

{"stockData":{"symbol":"000739","market":"SZ","secType":"STK","nameCN":"普洛药业","latestPrice":16.4,"timestamp":1774249434000,"preClose":16.52,"halted":0,"volume":13674776,"delay":0,"changeRate":-0.0073,"floatShares":1158000000,"shares":1158000000,"eps":0.6477,"marketStatus":"已收盘","change":-0.12,"latestTime":"03-23 15:00:00","open":16.23,"high":16.54,"low":16.03,"amount":223000000,"amplitude":0.0309,"askPrice":16.4,"askSize":112,"bidPrice":16.39,"bidSize":307,"shortable":0,"etf":0,"ttmEps":0.6477,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774315800000},"marketStatusCode":5,"adr":0,"adjPreClose":16.52,"symbolType":"stock","openAndCloseTimeList":[[1774229400000,1774236600000],[1774242000000,1774249200000]],"highLimit":18.17,"lowLimit":14.87,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1158443576,"isCdr":false,"pbRate":3.02,"roa":"--","peRate":25.320364,"roe":"13.22%","epsLYR":0.7723,"committee":0.360308,"marketValue":18998000000,"turnoverRate":0.0118,"status":1,"floatMarketCap":18991000000},"requestUrl":"/m/hq/s/000739","defaultTab":"news","newsList":[{"id":"2621747382","title":"【机构调研记录】博远基金调研普洛药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2621747382","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621747382?lang=zh_cn&edition=full","pubTime":"2026-03-23 08:01","pubTimestamp":1774224093,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及3月20日披露的机构调研信息，博远基金近期对1家上市公司进行了调研，相关名单如下：1）普洛药业 调研纪要：公司原料药及CDMO原料价格平均上涨约12%，占成本比重增加6-8个百分点，硫酸、溴素等受外部因素影响涨幅明显。博远基金成立于2018年，截至目前，资产管理规模69.17亿元，排名152/212；资产管理规模69.17亿元，排名131/212；管理公募基金数15只，排名143/212；旗下公募基金经理5人，排名146/212。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300002090.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0188","000739","BK0239"],"gpt_icon":0},{"id":"2620786504","title":"3月20日普洛药业跌7.45%，大成睿享混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2620786504","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620786504?lang=zh_cn&edition=full","pubTime":"2026-03-20 16:20","pubTimestamp":1773994832,"startTime":"0","endTime":"0","summary":"证券之星消息，3月20日普洛药业跌7.45%，收盘报16.52元，换手率2.26%，成交量26.16万手，成交额4.37亿元。重仓普洛药业的前十大公募基金请见下表：该股最近90天内共有4家机构给出评级，买入评级3家，增持评级1家；过去90天内机构目标均价为21.0。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共20家，其中持有数量最多的公募基金为大成基金的大成睿享混合A。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000027633.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000739","BK0060","BK0188","BK0239"],"gpt_icon":0},{"id":"2620228346","title":"普洛药业最新公告：2025年净利润同比下降13.62%，拟每10股派2.38元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620228346","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620228346?lang=zh_cn&edition=full","pubTime":"2026-03-19 20:30","pubTimestamp":1773923406,"startTime":"0","endTime":"0","summary":"普洛药业(000739.SZ)公告称，公司2025年实现营业收入97.84亿元，同比下降18.62%；归属于上市公司股东的净利润为8.91亿元，同比下降13.62%。公司拟以1,127,631,276股为基数，向全体股东每10股派发现金红利2.38元(含税)，不送红股，不以公积金转增股本。报告期内，CDMO业务收入同比增长16.66%至21.98亿元，原料药中间体业务收入同比下降28.74%至61.65亿元，药品业务收入同比下降8.42%至11.50亿元。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031900036038.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000739"],"gpt_icon":0},{"id":"2618937458","title":"普洛药业(000739.SZ)拟推2026年股票期权激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2618937458","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618937458?lang=zh_cn&edition=full","pubTime":"2026-03-10 19:54","pubTimestamp":1773143667,"startTime":"0","endTime":"0","summary":"智通财经APP讯，普洛药业(000739.SZ)发布2026年股票期权激励计划(草案)，拟向激励对象授予的股票期权数量为759.70万份，约占本激励计划草案公告时公司股本总额的0.66%，其中，首次授予608.40万份，预留151.30万份。行权价格为13.38元/份。此次激励计划有效期自股票期权首次授予之日起至激励对象获授的股票期权全部行权或注销之日止，最长不超过60个月。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412287.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0060","BK0239","000739"],"gpt_icon":0},{"id":"2618600918","title":"普洛药业参与行业对话，共探行业高质量发展新机遇！","url":"https://stock-news.laohu8.com/highlight/detail?id=2618600918","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618600918?lang=zh_cn&edition=full","pubTime":"2026-03-10 11:16","pubTimestamp":1773112560,"startTime":"0","endTime":"0","summary":"作为全球领先的一站式CDMO服务企业，普洛药业股份有限公司携全链条多肽技术平台参加盛会，通过专业展台展示、技术深度交流、圆桌对话研讨等多元形式，与业内专家围绕“多肽药物产业化的CMC攻坚与创新破局”这一核心议题进行深入探讨，共话多肽药物产业发展的新趋势，共探行业高质量发展的新机遇。据介绍，普洛药业CDMO多肽平台致力于为多肽药物开发提供全面、端到端的服务。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-03-10/doc-inhqnmhs6364518.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","162414","BK0188","BK0060","000739"],"gpt_icon":0},{"id":"2617542757","title":"普洛药业：公司2025年年报将于3月20日披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2617542757","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617542757?lang=zh_cn&edition=full","pubTime":"2026-03-05 20:52","pubTimestamp":1772715161,"startTime":"0","endTime":"0","summary":"证券之星消息，普洛药业(000739)03月05日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，您好。2025年的业绩是否不能达到预期目标！禹山运动公司增持股份进展情况如何？谢谢！普洛药业回复：投资者您好！公司2025年年报将于3月20日披露；控股股东一致行动人增持公司股份还在进行中，其进展将按照相关规定进行披露。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030500037412.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","000739","BK0188","BK0239"],"gpt_icon":0},{"id":"2614185003","title":"普洛药业（000739）披露对下属公司担保进展公告，2月27日股价下跌0.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614185003","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614185003?lang=zh_cn&edition=full","pubTime":"2026-02-27 23:35","pubTimestamp":1772206514,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，普洛药业报收于18.07元，较前一交易日下跌0.5%，最新总市值为209.33亿元。该股当日开盘18.16元，最高18.35元，最低18.03元，成交额达9882.92万元，换手率为0.47%。近日，普洛药业发布《关于对下属公司担保的进展公告》。截至目前，公司对家园药业的担保余额为83,000万元，公司对下属子公司的担保余额合计372,638万元，占2024年度经审计净资产的55.27%，无逾期担保。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700043417.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0188","BK0239","000739"],"gpt_icon":0},{"id":"2609883615","title":"股市必读：普洛药业（000739）2月5日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2609883615","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609883615?lang=zh_cn&edition=full","pubTime":"2026-02-06 01:15","pubTimestamp":1770311711,"startTime":"0","endTime":"0","summary":"截至2026年2月5日收盘，普洛药业报收于18.8元，下跌0.95%，换手率0.67%，成交量7.76万手，成交额1.46亿元。请广大投资者以公司披露的公告为准，谨慎分析判断，注意投资风险。来自交易信息汇总：散户资金净流入104.02万元，表明散户情绪相对稳定。交易信息汇总资金流向2月5日主力资金净流出1526.9万元；游资资金净流入1422.88万元；散户资金净流入104.02万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600001217.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0188","BK0239","000739"],"gpt_icon":0},{"id":"2609329831","title":"普洛药业：CDMO项目数持续保持较快增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2609329831","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609329831?lang=zh_cn&edition=full","pubTime":"2026-02-05 15:15","pubTimestamp":1770275725,"startTime":"0","endTime":"0","summary":"证券之星消息，普洛药业02月05日在投资者关系平台上答复投资者关心的问题。近年来，公司CDMO项目数持续保持较快增长，且逐渐进入商业化生产阶段，有助于CDMO产能利用率的回升；但公司CDMO项目与产能涉及多个子公司、众多生产线，部分产线的生产旺盛并不完全代表公司整体业务情况，也不构成对公司经营业绩的预期指引。请广大投资者以公司披露的公告为准，谨慎分析判断，注意投资风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500018994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000739","BK0060","BK0188"],"gpt_icon":0},{"id":"2607041104","title":"普洛药业（000739）披露对下属公司担保进展公告，1月30日股价下跌4.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607041104","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607041104?lang=zh_cn&edition=full","pubTime":"2026-01-30 22:36","pubTimestamp":1769783780,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，普洛药业报收于18.36元，较前一交易日下跌4.13%，最新总市值为212.69亿元。该股当日开盘18.98元，最高19.17元，最低18.19元，成交额达2.18亿元，换手率为1.01%。近日，普洛药业披露《关于对下属公司担保的进展公告》。截至目前，公司对上述子公司的担保余额分别为80,000万元、157,500万元、37,058万元。本次担保后，公司对下属公司担保余额为369,638万元，占2024年度经审计净资产的54.83%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000047543.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","BK0188","000739"],"gpt_icon":0},{"id":"2606791211","title":"普洛药业（000739）披露签署战略合作框架协议，1月28日股价下跌1.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606791211","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606791211?lang=zh_cn&edition=full","pubTime":"2026-01-28 17:35","pubTimestamp":1769592952,"startTime":"0","endTime":"0","summary":"截至2026年1月28日收盘，普洛药业报收于18.76元，较前一交易日下跌1.88%，最新总市值为217.32亿元。该股当日开盘19.12元，最高19.17元，最低18.53元，成交额达2.27亿元，换手率为1.05%。近日，普洛药业股份有限公司与杭州德睿智药科技有限公司签署《战略合作框架协议》，双方将在创新药研发与外包定制生产领域开展长期合作。本次签约对公司本年度经营业绩无重大影响，未来影响将视具体项目实施情况而定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800030306.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000739","BK0188","BK0239","BK0060"],"gpt_icon":0},{"id":"2606207237","title":"普洛药业最新公告：与德睿智药签订战略合作框架协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2606207237","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606207237?lang=zh_cn&edition=full","pubTime":"2026-01-27 17:50","pubTimestamp":1769507430,"startTime":"0","endTime":"0","summary":"普洛药业(000739.SZ)公告称，公司与杭州德睿智药科技有限公司签订《战略合作框架协议》，结成战略合作伙伴，开展CDMO项目的长期合作。该协议不涉及实质性交易，不构成关联交易或重大资产重组。对公司本年度经营业绩不构成重大影响，对未来年度经营业绩的影响将视具体项目协议和实施情况而定。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700030337.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","000739","BK0060"],"gpt_icon":0},{"id":"2606751240","title":"股市必读：普洛药业（000739）1月26日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2606751240","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606751240?lang=zh_cn&edition=full","pubTime":"2026-01-27 02:10","pubTimestamp":1769451022,"startTime":"0","endTime":"0","summary":"截至2026年1月26日收盘，普洛药业报收于19.36元，上涨4.65%，换手率1.71%，成交量19.83万手，成交额3.79亿元。董秘最新回复投资者： 董秘，您好！公司的创新药注射用索法地尔的III期临床试验，基于临床研究进展及后续研发投入等因素的综合评估，已于2024年终止。公司暂无在原有研发基础上重新启动临床试验的计划。当日关注点来自交易信息汇总：1月26日主力资金净流入812.06万元，游资积极介入推升市场热度。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700001730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0060","000739"],"gpt_icon":0},{"id":"2603455776","title":"股市必读：普洛药业（000739）1月14日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2603455776","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603455776?lang=zh_cn&edition=full","pubTime":"2026-01-15 01:20","pubTimestamp":1768411217,"startTime":"0","endTime":"0","summary":"截至2026年1月14日收盘，普洛药业报收于17.55元，下跌1.35%，换手率2.87%，成交量33.27万手，成交额5.8亿元。公司拟于2026年3月20日披露2025年年度报告，敬请关注公告。来自公司公告汇总：控股股东一致行动人单日增持公司股份0.14%，并披露未来六个月内拟累计增持金额不低于6000万元且不超过1.2亿元。本次权益变动后，控股股东及其一致行动人合计持股比例达52.03%，触及1%整数倍。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500000931.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","BK0188","000739"],"gpt_icon":0},{"id":"2603769990","title":"普洛药业：创新药索法地尔III期临床试验已终止","url":"https://stock-news.laohu8.com/highlight/detail?id=2603769990","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603769990?lang=zh_cn&edition=full","pubTime":"2026-01-14 17:21","pubTimestamp":1768382474,"startTime":"0","endTime":"0","summary":"证券之星消息，普洛药业(000739)01月14日在投资者关系平台上答复投资者关心的问题。投资者提问：请问，公司目前的创新药索法地尔进衣如何？请详细介绍，谢谢！普洛药业回复：投资者您好！公司的创新药注射用索法地尔的 III 期临床试验，基于临床研究进展及后续研发投入等因素的综合评估，已于2024年终止，详见公司公告（公告编号：2024-02）。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400028961.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","06978","BK1161","BK0060","BK0239","BK0188","BK1574","000739"],"gpt_icon":0},{"id":"2603685787","title":"普洛药业最新公告：控股股东之一致行动人拟0.6亿元-1.2亿元增持公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2603685787","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603685787?lang=zh_cn&edition=full","pubTime":"2026-01-13 19:49","pubTimestamp":1768304969,"startTime":"0","endTime":"0","summary":"普洛药业(000739.SZ)公告称，公司控股股东之一致行动人东阳市横店禹山运动休闲有限公司1月13日以集中竞价交易方式增持公司股份165.35万股，占公司总股本的0.14%，增持金额共计2869.6万元。禹山运动计划自1月13日起6个月内，以自有资金或自筹资金0.6亿元—1.2亿元（包含已增持的2869.6万元）通过集中竞价交易方式增持公司股份。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300037125.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000739","BK0060","BK0188","BK0239"],"gpt_icon":0},{"id":"2603575929","title":"异动快报：普洛药业（000739）1月13日10点12分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2603575929","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603575929?lang=zh_cn&edition=full","pubTime":"2026-01-13 10:15","pubTimestamp":1768270526,"startTime":"0","endTime":"0","summary":"证券之星1月13日盘中消息，10点12分普洛药业触及涨停板。其所属行业化学制药目前上涨。领涨股为尔康制药。该股为减肥药，创新药，合成生物概念热股，当日减肥药概念上涨4.18%，创新药概念上涨3.28%，合成生物概念上涨2.69%。1月12日的资金流向数据方面，主力资金净流出1110.54万元，占总成交额8.05%，游资资金净流入1054.19万元，占总成交额7.65%，散户资金净流入56.35万元，占总成交额0.41%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300011023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0060","BK0239","000739"],"gpt_icon":0},{"id":"2602550506","title":"股市必读：普洛药业（000739）1月9日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2602550506","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602550506?lang=zh_cn&edition=full","pubTime":"2026-01-12 03:32","pubTimestamp":1768159929,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，普洛药业报收于16.37元，上涨0.43%，换手率0.61%，成交量7.06万手，成交额1.15亿元。来自公司公告汇总：普洛药业完成2025年第二次股份回购，累计回购22,090,000股，占总股本1.91%，回购金额达3.6亿元上限。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200001488.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000739","BK0239","BK0060"],"gpt_icon":0},{"id":"2602375996","title":"普洛药业：CDMO业务成业绩增长主引擎","url":"https://stock-news.laohu8.com/highlight/detail?id=2602375996","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602375996?lang=zh_cn&edition=full","pubTime":"2026-01-09 20:48","pubTimestamp":1767962927,"startTime":"0","endTime":"0","summary":"证券之星消息，普洛药业01月09日在投资者关系平台上答复投资者关心的问题。公司股价受宏观环境、政策形势、行业周期和经营业绩等多种因素影响，近期公司股价较为平稳。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900037994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","000739","BK0239","BK0188"],"gpt_icon":0},{"id":"2601867574","title":"普洛药业(000739.SZ)与西安新通签署战略合作框架协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2601867574","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601867574?lang=zh_cn&edition=full","pubTime":"2026-01-06 16:27","pubTimestamp":1767688060,"startTime":"0","endTime":"0","summary":"智通财经APP讯，普洛药业(000739.SZ)公告，公司作为乙方与西安新通药物研究股份有限公司(简称“西安新通”、甲方)近日签订了《战略合作框架协议》，旨在开展创新药研发与外包定制生产项目(“CDMO项目”)的长期合作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389277.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"普洛药业(000739.SZ)与西安新通签署战略合作框架协议","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000739","BK0060","BK0188","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774281732059,"stockEarnings":[{"period":"1week","weight":-0.0822},{"period":"1month","weight":-0.0908},{"period":"3month","weight":-0.0167},{"period":"6month","weight":0.0018},{"period":"1year","weight":0.1392},{"period":"ytd","weight":0.0154}],"compareEarnings":[{"period":"1week","weight":-0.0338},{"period":"1month","weight":-0.0306},{"period":"3month","weight":0.0171},{"period":"6month","weight":0.0359},{"period":"1year","weight":0.1608},{"period":"ytd","weight":-0.003}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"普洛药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"34161人(较上一季度减少4.05%)","perCapita":"33898股","listingDate":"1997-05-09","address":"浙江省金华市东阳市横店江南路399号","registeredCapital":"115844万元","survey":"　　普洛药业股份有限公司的主营业务是创新药研发生产服务（CDMO）、原料药中间体、药品等研发、生产和销售以及进出口贸易业务。公司的主要产品及服务是原料药中间体、创新药研发生产服务、药品、其他。公司荣登“2024年度中国医药工业主营业务收入”第36位；获评国家发改委“先进制造业与现代服务业融合发展试点项目”单位和国家级“绿色工厂”荣誉称号；荣获“中国上市公司百强高成长企业奖”，连续五年在深圳证券交易所上市公司年度信息披露工作评价中获评最高评级A级；荣获2025“上证鹰·金质量”公司治理奖等。","listedPrice":5.7},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"普洛药业(000739)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供普洛药业(000739)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"普洛药业,000739,普洛药业股票,普洛药业股票老虎,普洛药业股票老虎国际,普洛药业行情,普洛药业股票行情,普洛药业股价,普洛药业股市,普洛药业股票价格,普洛药业股票交易,普洛药业股票购买,普洛药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"普洛药业(000739)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供普洛药业(000739)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}